Progression-free survival from the time of randomization between observation and rituximab maintenance in the PRIMA study. Progression-free survival according to FCGR3A alleles in the observation arm (Ai) and rituximab arm (Aii) and according to FCGR2A alleles in the observation arm (Bi) and rituximab arm (Bii).